Back to Journals » Lung Cancer: Targets and Therapy » Volume 10

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date

Authors Facchinetti F, Friboulet L

Received 15 June 2019

Accepted for publication 30 August 2019

Published 9 September 2019 Volume 2019:10 Pages 87—94


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Sai-Hong Ignatius Ou

Francesco Facchinetti, Luc Friboulet

INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France

Correspondence: Francesco Facchinetti
INSERM U981, Gustave Roussy Cancer Campus, 114 Rue Edouard, Villejuif 94800, France
Tel + 33 14 211 5662

Abstract: ROS1 inhibition provides impressive survival benefits in ROS1-rearranged non-small cell lung cancer (NSCLC) patients. Crizotinib is the only tyrosine kinase inhibitor (TKI) approved by both FDA and EMA for the treatment of ROS1-positive lung cancer. In addition, several TKI have been tested with preliminary proofs of success in this oncogene-driven disease, either in the post-crizotinib setting or as first-line targeted agents. Here we present the evidence concerning entrectinib, an ALK/ROS1/NTRK inhibitor developed across different tumor types harboring rearrangements in these genes, in the context of ROS1-driven NSCLC. Of interest, in August 2019 entrectinib was granted by FDA accelerated approval for the treatment of ROS1-rearranged NSCLC, as well as of NTRK-driven solid tumors.

Keywords: lung cancer, ROS1, tyrosine kinase inhibitors, entrectinib

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]